Dapagliflozin 10 MG [Farxiga]

DRUG9 trials

Conditions

Atrial Fibrillation RecurrentCardiac CatheterizationCatheter AblationChronic Kidney DiseasesChronic Thromboembolic Pulmonary HypertensionCoronary Disease With Diabetes MellitusDiabetes Mellitus, Type 2End Stage Renal Disease

Phase 1

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

CompletedNCT04545411

University of California, San DiegoType 1 Diabetes

Start: 2021-02-22End: 2022-10-31Updated: 2023-01-23

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Active, not recruitingNCT05719714

Northwestern UniversityChronic Kidney Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction +1

Start: 2024-01-16End: 2026-09-30Updated: 2026-07-30

Phase 2

Dapagliflozin in Pulmonary Arterial Hypertension

CompletedNCT05179356

Mads ErsbøllChronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension

Start: 2023-01-01End: 2026-01-13Updated: 2026-01-21

Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment

NCT05250752

Holbaek SygehusEnd Stage Renal Disease, Peritoneal Dialysis Complication

Start: 2021-11-18End: 2022-12-31Target: 10Updated: 2022-02-22

Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation

Active, not recruitingNCT06111443

Chang Gung Memorial HospitalAtrial Fibrillation Recurrent, Catheter Ablation

Start: 2023-12-01End: 2026-11-30Target: 196Updated: 2023-12-21

Phase 4

Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease

NCT03398577

Sheba Medical CenterCoronary Disease With Diabetes Mellitus

Start: 2018-02-01End: 2018-12-31Target: 61Updated: 2018-01-17

Dapagliflozin Treatment in Type 2 Diabetes

CompletedNCT04620590

Emerald Clinical Inc.Diabetes Mellitus, Type 2, Impaired Renal Function

Start: 2021-04-20End: 2023-11-30Updated: 2025-04-24

Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF

NCT04739215

Hospital General Universitario Gregorio MarañonDiabetes Mellitus, Type 2, Heart Failure With Preserved Ejection Fraction

Start: 2021-01-15End: 2022-12-30Target: 62Updated: 2021-02-04

Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

NCT05225077

Dong-A UniversityCardiac Catheterization, Percutaneous Coronary Intervention, Renal Insufficiency, Chronic

Start: 2022-01-01End: 2023-12-31Target: 600Updated: 2022-02-04

Related Papers

Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: The DAPAH randomized controlled trial.